Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4336531 | 0.85 | MAPT (0.71) | MAPTALDH1A1SMN1; SMN2CYP1A2KDM4E | |
| SCHEMBL2457450 | 0.85 | NPC1 (0.61) | MAPTALDH1A1SMN1; SMN2CYP1A2KDM4E | |
| SCHEMBL2626726 | 0.85 | SMN1; SMN2 (0.61) | MAPTALDH1A1SMN1; SMN2CYP1A2KDM4E | |
| SCHEMBL31133246 | 0.85 | SMN1; SMN2 (0.61) | MAPTALDH1A1SMN1; SMN2CYP1A2KDM4E | |
| SCHEMBL7012617 | 0.85 | PDE4B (0.67) | MAPTALDH1A1KDM4EPDE4BNPC1 | |
| SCHEMBL6290555 | 0.83 | MAPT (0.69) | MAPTALDH1A1SMN1; SMN2CYP1A2KDM4E | |
| SCHEMBL10725206 | 0.82 | PDE4B (0.58) | PDE4BPDE5A | |
| SCHEMBL2457003 | 0.82 | MAPT (0.67) | MAPTALDH1A1SMN1; SMN2CYP1A2KDM4E | |
| SCHEMBL10960814 | 0.81 | PDE4B (0.57) | MAPTPDE4BPDE5AMEN1HPGD | |
| SCHEMBL6290508 | 0.80 | PDE4B (0.62) | MAPTALDH1A1SMN1; SMN2KDM4EPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012470-B2 | Therapeutic 5,6,5-tricyclic analogs | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-04-21 | — | — | US | disclosed |
| US-20120095016-A1 | THERAPEUTIC 5,6,5-TRICYCLIC ANALOGS | HELICON THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095016-A1 | THERAPEUTIC 5,6,5-TRICYCLIC ANALOGS | GABRA5, GABRA6, GABRB1 | MAPT 1700/4885ALDH1A1 500/4885SMN1; SMN2 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.